Latest News for: crispr

Edit

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing ...

Enid News & Eagle 17 Feb 2026
BOULDER, Colo.--(BUSINESS WIRE)--Feb 17, 2026-- ... .
Edit

CRISPR breakthrough: Scientists from China remove HIV DNA from infected cells

India Today 16 Feb 2026
CRISPR breakthrough Scientists from China remove HIV DNA from infected cells ... .
Edit

Advancing CRISPR Precision: Liposome-Encapsulated Nucleic Acids and LNP Delivery Gain Momentum with Support from Creative Biolabs

GetNews 16 Feb 2026
Creative Biolabs provides end-to-end scientific support—from liposomal formulation design to next-generation LNP platforms tailored for CRISPR-Cas9, RNPs, and emerging editing tools ... LNP Delivery for CRISPR.
Edit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Nasdaq Globe Newswire 12 Feb 2026
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq. CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025 ... .
Edit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (CRISPR Therapeutics AG)

Public Technologies 12 Feb 2026
12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... CRISPR Therapeutics continues to advance its in vivo hematopoietic stem cell editing approach utilizing lipid nanoparticle (LNP)-mediated delivery through preclinical studies.
Edit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (Form 8-K) (CRISPR Therapeutics AG)

Public Technologies 12 Feb 2026
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results. ZUG, Switzerland and BOSTON, February 12, 2026 - CRISPR Therapeutics (Nasdaq ... About CRISPR Therapeutics.
Edit

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) (CRISPR Therapeutics AG)

Public Technologies 12 Feb 2026
We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology ... In 2023, CASGEVY became the first-ever approved CRISPR-based gene-editing therapy in the world.
Edit

AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation

Nasdaq Globe Newswire 10 Feb 2026
As AI continues to move beyond software and automation, its impact on genomics and gene editing is becoming increasingly tangible ... .
Edit

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion ...

Nasdaq Globe Newswire 09 Feb 2026
Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene ...
Edit

New CRISPR tool spreads through bacteria to disable antibiotic resistance genes

Phys Dot Org 06 Feb 2026
....
Edit

CRISPR screen maps 250 genes essential for human muscle fiber formation

Phys Dot Org 05 Feb 2026
....
Edit

CRISPR-based biosensors enable real-time ocean health monitoring

Phys Dot Org 05 Feb 2026
....
Edit

CRISPR grapefruit without the bitterness are now in development

New Scientist 02 Feb 2026
Gene-editing citrus fruits to make them less bitter could not only encourage more people to eat them, it might also help save the industry from a devastating plague ... .
Edit

Crispr therapies will change medicine but there will be challenges along the way

Chemistry World 29 Jan 2026
The first treatments making use of Crispr gene editing may suffer some early hiccups ....
Edit

In 2023, the UK was the first country to approve a Crispr therapy. How’s it doing?

Chemistry World 29 Jan 2026
Disconnect exists between the media hype around gene-editing treatment and the reality for patients ....

Article Search

tools
×
×
×
×